Ascendis Pharma Files 6-K with Q3 2024 Financials
Ticker: ASND · Form: 6-K · Filed: Nov 14, 2024 · CIK: 1612042
Sentiment: neutral
Topics: financials, quarterly-report, sec-filing
TL;DR
Ascendis Pharma dropped its Q3 2024 financials, check the numbers for the latest.
AI Summary
Ascendis Pharma A/S filed a 6-K report on November 14, 2024, detailing financial information as of September 30, 2024. The filing includes data on financial assets, derivatives, issued capital, and profit/loss for various periods, including the nine months ended September 30, 2024, and the full year 2023.
Why It Matters
This filing provides investors with an update on Ascendis Pharma's financial position and performance, crucial for evaluating the company's stability and growth prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing an update on financial data, not a material event announcement.
Key Numbers
- Q3 Sep 30, 2024 — Financial Reporting Period (Indicates the latest quarterly financial data available in the filing.)
- 2023-12-31 — Previous Fiscal Year End (Provides a comparative point for financial performance and position.)
Key Players & Entities
- Ascendis Pharma A/S (company) — Filer of the report
- 20240930 (date) — Period of report
- 20241114 (date) — Filing date
FAQ
What is the reported profit or loss for the nine months ended September 30, 2024?
The filing indicates data for 'ProfitLossMember' for the period 2024-01-01 to 2024-09-30, but specific dollar amounts are not detailed in this header information.
What was the company's financial position as of December 31, 2023?
The filing references data points such as 'ifrs-full:SharePremiumMember' and 'ifrs-full:FairValueHierarchyCarryingAmountMember' for 2023-12-31, indicating financial details from the previous year-end.
Does the filing mention any restatements of prior period financial information?
Yes, the filing includes 'srt:RestatementAdjustmentMember' for the period 2023-01-01 to 2023-12-31, suggesting potential adjustments to prior financial data.
What types of financial assets are detailed in the report?
The report mentions 'ifrs-full:FinancialAssetsAtAmortisedCostMember' as of September 30, 2024.
Are there details on share-based compensation plans?
Yes, the filing references 'asnd:RestrictedStockUnitsMember' and 'asnd:PerformanceStockUnitsMember' for various periods, including 2024.
Filing Stats: 4,290 words · 17 min read · ~14 pages · Grade level 16.9 · Accepted 2024-11-14 16:15:19
Filing Documents
- asnd-20240930.htm (6-K) — 1836KB
- img148563435_0.jpg (GRAPHIC) — 21KB
- img148563435_1.jpg (GRAPHIC) — 82KB
- img148563435_2.jpg (GRAPHIC) — 48KB
- img148563435_3.jpg (GRAPHIC) — 16KB
- img148563435_4.jpg (GRAPHIC) — 18KB
- img148563435_5.jpg (GRAPHIC) — 188KB
- img148563435_6.jpg (GRAPHIC) — 24KB
- img148563435_7.jpg (GRAPHIC) — 19KB
- 0000950170-24-127079.txt ( ) — 7470KB
- asnd-20240930.xsd (EX-101.SCH) — 1045KB
- asnd-20240930_htm.xml (XML) — 1101KB
Financial Statements
Financial Statements This report contains the Company's Unaudited Condensed Consolidated Interim Financial Statements as of and for the period ended September 30, 2024, including Management's Discussion and Analysis of Financial Condition and Results of Operations for the period presented therein.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ascendis Pharma A/S Date: November 14, 2024 By: /s/ Michael Wolff Jensen Michael Wolff Jensen Executive Vice President, Chief Legal Officer TABLE OF CONTENTS 1. Unaudited Condensed Consolidated Interim Financial Statements – September 30, 2024 F- 1 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 1 ASCENDIS PHARMA A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) for the Three and Nine Months Ended September 30, 2024 and 2023 F-2 Unaudited Condensed Consolidated Interim Statements of Financial Position as of September 30, 2024 and December 31, 2023 F-3 Unaudited Condensed Consolidated Interim Statements of Changes in Equity at September 30, 2024 and 2023 F-4 Unaudited Condensed Consolidated Interim Cash Flow Statements for the Nine Months Ended September 30, 2024 and 2023 F-5 Notes to the Unaudited Condensed Consolidated Interim Financial Statements F-6 F- 1 Unaudited Conden sed Consolidated Interim Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) for the Three and Nine Months Ended September 30, 2024 and 2023 Three Months Ended September 30, Nine Months Ended September 30, Notes 2024 2023 2024 2023 (EUR'000) (EUR'000) Consolidated Statement of Profit or (Loss) Revenue 5 57,833 48,034 189,725 129,016 Cost of sales 11,201 7,388 30,235 24,938 Gross profit 46,632 40,646 159,490 104,078 Research and development costs 73,544 111,439 227,708 322,573 Selling, general, and administrative expenses 69,831 63,614 210,928 200,435 Operating profit/(loss) ( 96,743 ) ( 134,407 ) ( 279,146 ) ( 418,930 ) Share of profit/(loss) of associates ( 4,367 ) ( 6,794 ) ( 15,485 ) ( 15,471 ) Finance income 28,279 4,142 29,262 76,985 Finance expenses 25,347 24,519 70,488 35,640 Profit/(loss) before tax ( 98,178 ) ( 161,578 ) ( 335,857 ) ( 393,056 ) Income taxes/(expenses) ( 1,020 ) ( 645 ) ( 3,758 ) ( 1,513 ) Net profit/(loss) for the period